JPRN-UMIN000008622已完成2 期
Exploratory study of Xeloda+CDDP(XP)+Trastuzumab therapy for advanced gastric cancer with HER2 positive CTCs - Exploratory study of Xeloda+CDDP(XP)+Trastuzumab therapy for advanced gastric cancer with HER2 positive CTCs
The Cancer Institute Hospital of JFCR0 个研究点目标入组 30 人开始时间: 2012年8月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Baseline left ventricular ejection fraction (LVEF) => 50% measured by echocardiography or MUGA scan (2)CNS metastases or brain cancer confirmed by imaging. (3) Patients who meet any of the following criteria will be excluded from the study. 1. Patient with a previous history of congestive heart failure 2. Unstable angina requiring med 3.Confirmed transmural myocardial infarction by ECG 4.Uncontrolled hypertension(SAP>180mmHg or DBP>=100mmHg) 5. Severe heart valve disease 6. Hi-risk uncontrolled arrhythmias (4) History of active double cancer within 5 year. (without healed cutaneous basal cell carcinomas and carcinoma in situ of the cervix, or digestive system cancer verified cure by endoscopic mucosal resection) (5) Severe pulmonary disease (Interstitial pneumonitis or pulmonary fibrosis) (6) History of the organ transplantation to need an immunosuppressive drug (7) Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Combination treatment with TS-1+CDDP+Trastuzumab for unresectable HER 2 positive gastric cancer (A Phase II Study)nresectable HER2 positive gastric cancerJPRN-UMIN000005876Toho University20
招募中
1 期
Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive.advanced or recurrent HER2-positive gastric cancerJPRN-UMIN000008623The Cancer Institute Hospital of JFCR36
进行中（未招募）
1 期
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast CancerEUCTR2020-004074-21-SEAstraZeneca AB1,134
进行中（未招募）
1 期
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast CancerHER2-positive metastatic breast cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004074-21-ITASTRAZENECA AB1,134
进行中（未招募）
1 期
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast CancerCTIS2023-505249-24-00AstraZeneca AB1,134